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The management of iron deficiency anaemia (IDA) in older individuals might appear 
relatively simple and uncontroversial. However, a combination of diagnostic challenges and 
increasing evidence for common treatments being poorly effective, arguably render this a 
false assumption. The long-established practice of prescribing oral ferrous supplements is 
increasingly challenged by the wider availability and promotion of modern intravenous iron 
supplementation. It has brought into focus the need for evidence of efficacy and cost-
effectiveness, particularly in terms of the balance of affordable person-centred benefits versus 
harm (‘realistic medicine’).  
 
Why iron deficiency matters 
Anaemia is a particularly common finding in older people. It is associated with fatigue, 
impaired functional capacity, increased hospitalization and mortality [1]. The World Health 
Organisation defines anaemia as a haemoglobin level <130g/L in men and <120g/L in 
women [2]. Its prevalence among community-dwelling adults aged 65 years and older in the 
USA is 11.0% and 10.2% in men and women, respectively, [3] rising to more than 20% in 
those >85 years and over 50% of those in nursing homes [4].  
 
IDA is relatively common, typically accounting for approximately 30% of cases of anaemia 
in older individuals in most Western countries [5,6]. It is diagnosed by the presence of low 
ferritin levels or low serum iron and transferrin saturation levels [7]. However, ferritin levels 
are higher in older people and increase in disease, making diagnosis less certain. In older 
people, chronic kidney disease, gastrointestinal problems and poor diet more commonly 
underpin anaemia [6]. Up to half of all elderly anaemic patients have multifactorial anaemia, 
characterised by a combination of underlying problems such as iron deficiency, chronic 
inflammation, renal insufficiency, folate deficiency and/or vitamin B12 deficiency. Thus, oral 
iron supplementation might only have a modest impact on haemoglobin level [8]. In a 
Scottish study, 5% of the population aged 65 or over received at least one prescription for 
oral iron in the year 2015-2016 [9]. Large numbers of people are therefore treated for iron 
deficiency, many for a long time, making the question of how to treat this condition most 
effectively an important one for patients, clinicians and healthcare funders. 
 
Do oral iron supplements really work? 
Despite the widespread use of oral iron to treat even mild IDA in older people, evidence is 
lacking on the best way to treat this condition, or indeed whether treatment is required at all 
in mild cases. A recent systematic review found only three RCTs in older people testing the 
efficacy of oral iron compared to placebo or no iron, all in the setting of orthopaedic surgery. 
The treatment effect was trivial; haemoglobin levels increased by a mean of only 3.5g/L 
(95%CI:1.2-5.9g/L) [10]. Routinely collected data from older people in Scotland support 
these findings with a mean improvement in Hb after treatment of only 5g/L in those with iron 
deficiency relative to those without treatment [9]. In an observational study involving 50,319 
adult chronic kidney disease patients, oral iron therapy was less effective than no iron 
replacement [11]. In another study, Rimon et al showed low dose oral iron treatment was as 
effective as higher dose in increasing haemoglobin in elderly people [12]. However, there 
was no placebo control group, so the absence of a dose-response association potentially 
suggests that oral iron is ineffective. The current practice of daily dosing and/or splitting 
doses might adversely affect iron absorption by increasing hepcidin levels [13], showing the 
need to re-evaluate our current knowledge on how best to administer oral iron.  
Hepcidin regulates entry of iron into the circulation but high hepcidin levels are also seen in 
chronic inflammation and chronic kidney disease resulting in reduced iron absorption from 
gut mucosa [14]. Also, iron supplements may not be well absorbed in those with atrophic 
gastritis (most of those aged 80 or over) or proton pump inhibitors due to achlorhydia [10]. 
Another important reason why oral iron may be ineffective is that adherence is poor due to 
side effects in up to 40% of people - particularly gastrointestinal symptoms with subsequent 
impact on diet, nutrition and health related quality of life [12, 15]. For a review of iron 
absorption and metabolism, see Anderson et al. [16].  
 
Is intravenous iron better? 
Intravenous iron can overcome many of the above problems with oral supplementation, but it 
is more expensive and carries a small, but non-trivial risk of anaphylactoid reactions. A meta-
analysis assessing safety and efficacy of intravenous iron in various clinical groups showed 
intravenous iron increased haemoglobin concentration (standardised mean difference 6.5 g/L, 
95% confidence interval 5.1 g/L to 7.9 g/L) and reduced risk of requirement for blood 
transfusion (risk ratio 0.74, 95% confidence interval 0.62 to 0.88). Side effects of IV iron 
were rare, occurring in 0.5 to 1% of the patients, including self-limiting fever, arthralgia and 
myalgia, usually within 24 hours of infusion. Anaphylactic reactions with IV high molecular 
weight iron dextran prohibited widespread use, but were extremely rare with other 
preparations of IV iron (<1:200,000) [17]. The efficacy and safety of IV iron in IDA in 
different settings suggest that IV iron supplementation could be considered for more elderly 
anaemic patients. However, whether the result of this meta–analysis applies to the elderly 
population is questionable. A further problem with the existing evidence for iron 
supplementation through any route is that the available trials did not aim to measure 
outcomes relevant to older patients – such as improvement in symptoms, physical 
performance, activities of daily living or quality of life [5, 9]. Moreover, a review of the 
evidence for intravenous iron found no precise comparison of the clinical benefit of different 
iron preparations [18]. There is better evidence of benefit in some specific patient groups, 
particularly those with heart failure and iron deficiency. However, even in this setting only 
one trial has demonstrated clear and consistent improvement in quality of life [19]. Patients in 
this trial had a mean age of only 67 years, so it is uncertain if this result can be generalised to 
other, older patient groups.   
 
 
The evidence gap 
A satisfactory response (>20g/L) to oral iron is usually expected within 6-8 weeks of 
commencing treatment but our research group’s data show many patients continue oral iron 
even if a suboptimal or no response is seen. The optimal dosing regimen and balance of 
benefit versus harm for oral iron in older people is unclear. The best strategy for those not 
responding to oral iron is also uncertain. It is also unclear whether further oral or IV iron 
therapy improves physical function and quality of life compared to no therapy in older 
patients with IDA.  
 
A recent survey of geriatricians and general practitioners carried out through the British 
Geriatrics Society confirmed uncertainties and inconsistent approaches to IDA in clinical 
practice across the UK (unpublished data). Improved medical education on the nuances of 
iron deficiency is needed. The treatment strategies for older people with IDA that do not 
respond to initial treatment should be explored. Evidence of clinical effectiveness using 
outcomes most relevant to older people, such as quality of life and functional ability, rather 
than haemoglobin levels, is urgently needed.   
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